Europe Therapeutic Vaccines Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
The Europe therapeutic vaccines market is projected to grow significantly, reaching approximately US$ 14.76 billion by 2031, up from US$ 6.39 billion in 2024, with a compound annual growth rate (CAGR) of 12.7% during the period from 2024 to 2031.
Executive Summary and Market Analysis
The therapeutic vaccines market in Europe is divided into several regions, including Germany, the UK, France, Italy, Spain, and the Rest of Europe. The growth of this market is driven by advanced healthcare systems and increased investments in research and development. Europe hosts numerous leading pharmaceutical and biotechnology companies that are dedicated to developing innovative vaccine therapies for various diseases, particularly cancer. The rising incidence of chronic diseases and the growing interest in personalized medicine are further propelling the demand for therapeutic vaccines in the region. The market is expected to continue its upward trajectory, bolstered by advancements in immunotherapy and the emergence of new vaccine technologies that present significant opportunities for growth.
Market Segmentation Analysis
The therapeutic vaccines market can be segmented based on product type, technology, and end user:
- By Product: The market includes cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
- By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines leading in market share in 2024.
- By End User: The end users are primarily hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.
Market Outlook
Therapeutic vaccines are designed to stimulate the immune system to treat conditions such as cancer, autoimmune diseases, and chronic infections. The increasing investments in vaccine development are crucial for the growth of the therapeutic vaccines market, fostering innovation and accelerating the creation of new treatments for chronic diseases. Over the last decade, global funding for vaccine R&D has surged, with governments, private entities, and pharmaceutical companies acknowledging the critical role of therapeutic vaccines in meeting unmet medical needs. For example, GlaxoSmithKline (GSK) allocated US$ 6.46 billion towards R&D in 2021, focusing on a pipeline that includes 43 medicines and 21 vaccines, with a significant portion targeting infectious diseases.
Moreover, there is a notable trend towards oncology-focused vaccines, with companies leveraging mRNA technology to develop therapeutic vaccines for various cancers. For instance, eTheRNA Immunotherapies received a €6.9 million grant from the European Commission to develop an innovative mRNA cancer vaccine for treating recurrent or metastatic HPV16+ cancers. Similarly, researchers at Queen's University Belfast secured funding to explore new treatments for triple-negative breast cancer, focusing on developing an mRNA vaccine that enhances the immune system's ability to target cancer cells with p53 mutations. Such funding initiatives are driving innovations in therapeutic vaccines, leading to more effective treatments for a range of diseases, including cancers and chronic infections.
Country Insights
The therapeutic vaccines market in Europe includes key countries such as Germany, Italy, France, the UK, Spain, and others, with Germany holding the largest market share in 2024. Germany boasts one of the most advanced healthcare systems globally, supported by a robust pharmaceutical and biotechnology sector that facilitates the development and commercialization of therapeutic vaccines. The country has a large patient population and a high demand for quality healthcare services. The increasing prevalence of chronic and infectious diseases, such as hepatitis B, further drives the market in Germany. For instance, in 2022, Germany reported 16,674 cases of hepatitis B.
Germany's strong research ecosystem, characterized by collaboration among academic institutions, hospitals, and biotech firms, is accelerating the development of new therapeutic vaccines. The German Cancer Research Center (DKFZ) is at the forefront of cancer immunotherapy research, contributing significantly to the country’s innovation landscape. In August 2024, DKFZ researchers introduced a novel vaccine aimed at increasing HPV vaccination rates, demonstrating efficacy in protecting against various cancer-causing HPV types.
Company Profiles
Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative products to consumers.
Reason to buy
Executive Summary and Market Analysis
The therapeutic vaccines market in Europe is divided into several regions, including Germany, the UK, France, Italy, Spain, and the Rest of Europe. The growth of this market is driven by advanced healthcare systems and increased investments in research and development. Europe hosts numerous leading pharmaceutical and biotechnology companies that are dedicated to developing innovative vaccine therapies for various diseases, particularly cancer. The rising incidence of chronic diseases and the growing interest in personalized medicine are further propelling the demand for therapeutic vaccines in the region. The market is expected to continue its upward trajectory, bolstered by advancements in immunotherapy and the emergence of new vaccine technologies that present significant opportunities for growth.
Market Segmentation Analysis
The therapeutic vaccines market can be segmented based on product type, technology, and end user:
- By Product: The market includes cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
- By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines leading in market share in 2024.
- By End User: The end users are primarily hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.
Market Outlook
Therapeutic vaccines are designed to stimulate the immune system to treat conditions such as cancer, autoimmune diseases, and chronic infections. The increasing investments in vaccine development are crucial for the growth of the therapeutic vaccines market, fostering innovation and accelerating the creation of new treatments for chronic diseases. Over the last decade, global funding for vaccine R&D has surged, with governments, private entities, and pharmaceutical companies acknowledging the critical role of therapeutic vaccines in meeting unmet medical needs. For example, GlaxoSmithKline (GSK) allocated US$ 6.46 billion towards R&D in 2021, focusing on a pipeline that includes 43 medicines and 21 vaccines, with a significant portion targeting infectious diseases.
Moreover, there is a notable trend towards oncology-focused vaccines, with companies leveraging mRNA technology to develop therapeutic vaccines for various cancers. For instance, eTheRNA Immunotherapies received a €6.9 million grant from the European Commission to develop an innovative mRNA cancer vaccine for treating recurrent or metastatic HPV16+ cancers. Similarly, researchers at Queen's University Belfast secured funding to explore new treatments for triple-negative breast cancer, focusing on developing an mRNA vaccine that enhances the immune system's ability to target cancer cells with p53 mutations. Such funding initiatives are driving innovations in therapeutic vaccines, leading to more effective treatments for a range of diseases, including cancers and chronic infections.
Country Insights
The therapeutic vaccines market in Europe includes key countries such as Germany, Italy, France, the UK, Spain, and others, with Germany holding the largest market share in 2024. Germany boasts one of the most advanced healthcare systems globally, supported by a robust pharmaceutical and biotechnology sector that facilitates the development and commercialization of therapeutic vaccines. The country has a large patient population and a high demand for quality healthcare services. The increasing prevalence of chronic and infectious diseases, such as hepatitis B, further drives the market in Germany. For instance, in 2022, Germany reported 16,674 cases of hepatitis B.
Germany's strong research ecosystem, characterized by collaboration among academic institutions, hospitals, and biotech firms, is accelerating the development of new therapeutic vaccines. The German Cancer Research Center (DKFZ) is at the forefront of cancer immunotherapy research, contributing significantly to the country’s innovation landscape. In August 2024, DKFZ researchers introduced a novel vaccine aimed at increasing HPV vaccination rates, demonstrating efficacy in protecting against various cancer-causing HPV types.
Company Profiles
Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative products to consumers.
Reason to buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Therapeutics Vaccine Market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe Therapeutics Vaccine Market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe Therapeutics vaccine Market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
- Dendreon
- BioNTech SE
- Serum Institute of India Pvt. Ltd
- Merck & Co Inc
- Amgen Inc
- ISA Pharmaceuticals BV
- INOVIO Pharmaceuticals Inc
- Transgene SA
- THERAVECTYS SA
- CureVac SE
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. EUROPE THERAPEUTIC VACCINES MARKET - KEY MARKET DYNAMICS
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic Conditions
4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
4.2.1 Regulatory Challenges
4.3 Market Opportunities
4.3.1 Extending Product Pipeline
4.4 Future Trends
4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:
5. THERAPEUTIC VACCINES MARKET - EUROPE MARKET ANALYSIS
5.1 Europe Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 Europe Therapeutic Vaccines Market Forecast Analysis
6. EUROPE THERAPEUTIC VACCINES MARKET ANALYSIS - BY PRODUCT
6.1 Cancer Vaccine
6.1.1 Overview
6.1.2 Cancer Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 infectious Disease Vaccine
6.2.1 Overview
6.2.2 infectious Disease Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
6.3.1 Overview
6.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7. EUROPE THERAPEUTIC VACCINES MARKET ANALYSIS - BY TECHNOLOGY
7.1 Allogenic Vaccine
7.1.1 Overview
7.1.2 Allogenic Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
7.2.1 Overview
7.2.2 Autologous Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8. EUROPE THERAPEUTIC VACCINES MARKET ANALYSIS - BY END USER
8.1 Hospitals
8.1.1 Overview
8.1.2 Hospitals: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
8.2.1 Overview
8.2.2 Clinics: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
8.3.1 Overview
8.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9. EUROPE THERAPEUTIC VACCINES MARKET - COUNTRY ANALYSIS
9.1 Europe
9.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.2 Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.2.1 Germany: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.2.2 Germany: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.2.3 Germany: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.3 United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.3.1 United Kingdom: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.3.2 United Kingdom: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.3.3 United Kingdom: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.4 France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.4.1 France: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.4.2 France: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.4.3 France: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.5 Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.5.1 Italy: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.5.2 Italy: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.5.3 Italy: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.6 Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.6.1 Spain: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.6.2 Spain: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.6.3 Spain: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.7 Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.7.1 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.7.2 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.7.3 Rest of Europe: Europe Therapeutic Vaccines Market Share - by End User
10. THERAPEUTIC VACCINES MARKET - INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Dendreon
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 BioNTech SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Merck & Co Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Amgen Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Transgene SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 THERAVECTYS SA
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 CureVac SE
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. APPENDIX
12.1 About The Insight Partners
12.2 Glossary of Terms
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. EUROPE THERAPEUTIC VACCINES MARKET - KEY MARKET DYNAMICS
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic Conditions
4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
4.2.1 Regulatory Challenges
4.3 Market Opportunities
4.3.1 Extending Product Pipeline
4.4 Future Trends
4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:
5. THERAPEUTIC VACCINES MARKET - EUROPE MARKET ANALYSIS
5.1 Europe Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 Europe Therapeutic Vaccines Market Forecast Analysis
6. EUROPE THERAPEUTIC VACCINES MARKET ANALYSIS - BY PRODUCT
6.1 Cancer Vaccine
6.1.1 Overview
6.1.2 Cancer Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 infectious Disease Vaccine
6.2.1 Overview
6.2.2 infectious Disease Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
6.3.1 Overview
6.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7. EUROPE THERAPEUTIC VACCINES MARKET ANALYSIS - BY TECHNOLOGY
7.1 Allogenic Vaccine
7.1.1 Overview
7.1.2 Allogenic Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
7.2.1 Overview
7.2.2 Autologous Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8. EUROPE THERAPEUTIC VACCINES MARKET ANALYSIS - BY END USER
8.1 Hospitals
8.1.1 Overview
8.1.2 Hospitals: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
8.2.1 Overview
8.2.2 Clinics: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
8.3.1 Overview
8.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9. EUROPE THERAPEUTIC VACCINES MARKET - COUNTRY ANALYSIS
9.1 Europe
9.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.2 Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.2.1 Germany: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.2.2 Germany: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.2.3 Germany: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.3 United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.3.1 United Kingdom: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.3.2 United Kingdom: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.3.3 United Kingdom: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.4 France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.4.1 France: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.4.2 France: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.4.3 France: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.5 Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.5.1 Italy: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.5.2 Italy: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.5.3 Italy: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.6 Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.6.1 Spain: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.6.2 Spain: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.6.3 Spain: Europe Therapeutic Vaccines Market Share - by End User
9.1.1.7 Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.7.1 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Product
9.1.1.7.2 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Technology
9.1.1.7.3 Rest of Europe: Europe Therapeutic Vaccines Market Share - by End User
10. THERAPEUTIC VACCINES MARKET - INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Dendreon
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 BioNTech SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Merck & Co Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Amgen Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Transgene SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 THERAVECTYS SA
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 CureVac SE
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. APPENDIX
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Therapeutic Vaccines Market Segmentation
Table 2. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Table 3. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
Table 4. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
Table 5. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
Table 6. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
Table 7. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 8. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 9. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 10. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 11. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 12. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 13. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 14. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 15. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 16. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 17. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 18. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 19. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 20. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 21. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 22. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 23. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 24. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 25. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
Table 26. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
Table 27. Glossary of Terms, Therapeutic Vaccines Market
Table 1. Europe Therapeutic Vaccines Market Segmentation
Table 2. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Table 3. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
Table 4. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
Table 5. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
Table 6. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
Table 7. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 8. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 9. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 10. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 11. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 12. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 13. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 14. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 15. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 16. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 17. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 18. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 19. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 20. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 21. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 22. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 23. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 24. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 25. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
Table 26. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
Table 27. Glossary of Terms, Therapeutic Vaccines Market
LIST OF FIGURES
Figure 1. Europe Therapeutic Vaccines Market Segmentation - Country
Figure 2. Europe Therapeutic Vaccines Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
Figure 5. Europe Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
Figure 6. Cancer Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 7. infectious Disease Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 8. Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 9. Europe Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
Figure 10. Allogenic Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 11. Autologous Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 12. Europe Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
Figure 13. Hospitals: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 14. Clinics: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 15. Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 16. Europe Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 17. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 18. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 19. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 20. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 21. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 22. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 23. Growth Strategies in the Therapeutic Vaccines Market
Figure 1. Europe Therapeutic Vaccines Market Segmentation - Country
Figure 2. Europe Therapeutic Vaccines Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
Figure 5. Europe Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
Figure 6. Cancer Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 7. infectious Disease Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 8. Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 9. Europe Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
Figure 10. Allogenic Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 11. Autologous Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 12. Europe Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
Figure 13. Hospitals: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 14. Clinics: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 15. Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 16. Europe Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 17. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 18. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 19. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 20. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 21. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 22. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 23. Growth Strategies in the Therapeutic Vaccines Market
